Top 5 Drug Type | Count |
---|---|
Small molecule drug | 20 |
Monoclonal antibody | 8 |
Recombinant polypeptide | 3 |
Antibody drug conjugate (ADC) | 2 |
Exosomes | 2 |
Target |
Mechanism SRC inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date14 Dec 2020 |
Target |
Mechanism HDAC inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. China |
First Approval Date23 Dec 2014 |
Target |
Mechanism BSG inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Feb 2025 |
Sponsor / Collaborator |
Start Date01 Jan 2025 |
Sponsor / Collaborator |
Start Date30 Oct 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Meplazumab ( BSG ) | COVID-19 More | Phase 2 |
Mertuzumab(Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd) ( BSG ) | Non-Small Cell Lung Cancer More | Phase 1 |
TriTE-N13 ( CD3 x CD80 x PSMA ) | Prostatic Cancer More | Preclinical |
Nuciferine ( D1 receptor x D2 receptor x TAS2R46 ) | Ischemic stroke More | Preclinical |
Biscoumarin derivative DCH | MRSA - Methicillin resistant Staphylococcus aureus infection More | Preclinical |